Change - Announcement of Appointment::Appointment of Executive Officer

Issuer & Securities

Issuer/ Manager
AJJ MEDTECH HOLDINGS LIMITED
Securities
AJJ MEDTECH HOLDINGS LIMITED - SG0584008601 - 584
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
13-Mar-2024 22:36:20
Status
New
Announcement Sub Title
Appointment of Executive Officer
Announcement Reference
SG240313OTHRVISG
Submitted By (Co./ Ind. Name)
Zhao Xin
Designation
Chief Executive Officer and Executive Director
Description (Please provide a detailed description of the event in the box below)
Appointment of Mr. Tan Wei Jie ("Mr. Tan") as an Executive Officer of the Company.

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited ("Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST").

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this notice, including the correctness of any of the statements or opinions made or reports contained in this notice.

The contact person for the Sponsor is Mr. Jerry Chua (Telephone Number: +65 6241 6626) at Evolve Capital Advisory Private Limited, 138 Robinson Road, #13-02, Oxley Tower, Singapore 068906.

Additional Details

Date Of Appointment
13/03/2024
Name Of Person
Tan Wei Jie
Age
32
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
Mr. Tan joined AJJ Healthcare Management Pte. Ltd. ("AJJ Healthcare"), a wholly owned subsidiary of the Company, since 11 October 2021 and is currently appointed as the Director of Business Development of AJJ Healthcare. The management and Board of Directors have observed that he has contributed significantly to the performance of AJJ Healthcare and the Group.

We have appointed Mr. Tan as the Director of Business Development, recognising his significant contributions, strong leadership, and immense potential for growth. His notable achievements in organising sales and stakeholder management have justified the Company's confidence in his abilities. As our organisation continues to expand, it is crucial to have leaders like Mr. Tan who embody our culture, align strongly with our mission, and possess the capability to lead effectively. This strategic decision leverages Mr. Tan's MedTech skills and achievements, positioning him as a key figure in our organisation's growth phase and ensuring our alignment with industry trends and regulatory standards. His appointment is pivotal in fostering our growth and enhancing our competitiveness in the healthcare market, demonstrating the vital role he plays in our future success.

Upon reviewing the qualifications and experience of Mr. Tan, and considering the recommendation by the management team and Nominating Committee, the Board of Directors approved the appointment of Mr. Tan as an executive officer of the Company.
Whether appointment is executive, and if so, the area of responsibility
The appointment is executive. As the Director of Business Development, Mr. Tan will play a more strategic role in forming strategic partnerships in Singapore, directing and implementing the sales and marketing strategy, and leading our sales operations. His responsibilities are crucial to ensure alignment with industry trends and regulatory standards, fostering growth, and maintaining competitiveness in the competitive healthcare market against global leaders.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Director of Business Development
Professional qualifications
Doctor of Philosophy - Nanyang Technological University, Singapore
Bachelor of Engineering (Materials Engineering) - Nanyang Technological University, Singapore
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Nil
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
October 2021 - Present
AJJ Healthcare Management Pte. Ltd.
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
AJJ Medtech Holdings Limited
Deemed Interest: 82,000

Subsidiaries of the Company: Nil
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Nil
Present
October 2021 - Present
AJJ Healthcare Management Pte. Ltd.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Not applicable